NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the “Class Period”), of the important September 3, 2024 lead plaintiff deadline. SO WHAT: If you purchased Bolt securities durig the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

CS Disco (LAW) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this legal technology company would post a loss of $0.12 per share when it actually produced a loss of $0.08, delivering a surprise of 33.33%.Over the last four quarters, the company has ...

公司概况 - 公司提供云原生、人工智能驱动的法律产品,简化法律保留、法律请求、电子发现、法律文件审查和案件管理[136] - 公司客户包括各行业的企业、律所、法律服务提供商和政府机构,销售主要通过直销团队[139,140] 收入情况 - 公司收入主要来自客户使用产品的实际使用量,客户可选择年度或多年期的最低使用量订阅[137] - 客户使用公司产品后,可增加使用量以覆盖更多法律事务,提高产品的战略价值和粘性[138] - 总收入同比增长5%，达到3.6005亿美元[172] - 软件产品收入增长8%，服务产品收入下降7%[174,175] - 总收入同比增长6%，达到7.1576亿美元[187,188] - 软件产品收入增长8%，服务产品收入下降3%[189] 成本费用 - 研发费用同比下降3%，主要由于人员成本和重组费用的减少[179,180] - 销售和营销费用同比下降14%，主要由于人员成本和重组费用的减少[181,182] - 一般管理费用同比下降2%，主要由于人员成本的减少[184,185] - 成本of revenue同比增长5%，主要由于云服务成本和人工成本的增加[191,192] - 研发费用同比下降14%，主要由于人员成本和重组费用的减少[193][194][195] - 销售和营销费用同比下降16%，主要由于销售人员人员成本和差旅费的减少[196][197] - 管理费用同比下降6%，主要由于人员成本和保险费用的减少[198][199] 财务状况 - 公司于2024年6月30日拥有1.3亿美元的现金和现金等价物[141] - 公司调整后EBITDA为负470万美元[143] - 公司现金和现金等价物为1.3亿美元，预计未来12个月内现金可以满足需求[204][205][206][207][208] - 经营活动现金流出同比下降63%，主要由于净亏损减少和应收账款回款增加[210][211][212] - 投资活动现金流出同比下降63%，主要由于收购支出减少和资本支出减少[213] - 融资活动现金流出同比增加1848%，主要由于股票回购支出增加[214] 其他 - 宏观经济不确定性可能对公司业务产生负面影响[144,145] - 公司调整了Adjusted EBITDA的计算方式，剔除了一些非经常性费用[200][201][202][203] - 公司采用公允价值确认的股票激励政策，根据授予日的公允价值确认为费用，并在服务期内摊销[218] - 公司CEO绩效股票期权的授予及后续注销情况[219][220][221] - 公司在并购时会根据被收购资产和负债的公允价值进行分配，并确认商誉，需要做出重大估计和假设[222] - 公司作为新兴成长公司可以享受JOBS法案的相关豁免政策[224] - 公司面临利率风险和汇率风险，但目前影响较小[225][226][227]

财务表现 - 总收入为3600万美元，同比增长5%[1] - 公司历史上首次实现季度收入超过3600万美元[1] - 公司2024年第二季度收入为3.6005亿美元，同比增长5.0%[21] - 公司2024年上半年收入为7.1576亿美元，同比增长6.2%[21] 业务发展 - 软件收入为2930万美元，同比增长8%[3] - 客户数量增加至1,449家[3] - 推出了新的大规模文档编辑功能和基于AI的文档摘要工具[3] - 任命了新的首席产品官[3] - 公司继续投资新产品和技术以提升客户体验[2] - 公司正在积极拓展国际市场[16] 财务预测 - 第三季度软件收入预计为2950万美元至3050万美元，全年软件收入预计为1.185亿美元至1.205亿美元[4] - 第三季度调整后EBITDA预计为-700万美元至-500万美元，全年调整后EBITDA预计为-2300万美元至-1900万美元[4] 财务指标 - 公司2024年第二季度毛利率为74.2%，同比提升1.9个百分点[24] - 公司2024年上半年毛利率为75.8%，同比提升0.8个百分点[24] - 公司2024年第二季度研发费用为1.2888亿美元，占收入的35.8%[25] - 公司2024年上半年研发费用为2.4967亿美元，占收入的34.9%[25] - 公司2024年第二季度销售及营销费用为1.5498亿美元，占收入的43.0%[26] - 公司2024年上半年销售及营销费用为3.1306亿美元，占收入的43.7%[26] - 公司2024年第二季度非GAAP调整后的经营亏损为5942万美元，经营亏损率为17.0%[28] - 公司2024年上半年非GAAP调整后的经营亏损为1.2402亿美元，经营亏损率为17.3%[28] - 净亏损归属于普通股股东为1.0834亿美元[29] - 非公认会计准则调整后的净亏损归属于普通股股东为4392万美元[29] - 非公认会计准则调整后的每股基本和稀释净亏损为0.07美元[29] - 非公认会计准则调整后的净亏损占收入的比例为12%[29] - 股票期权费用为6058万美元[29] - 重组费用为1574万美元[29] - 与股东诉讼相关的费用为384万美元[29] - 加权平均普通股股数为5.9815亿股[29] - 非公认会计准则调整后的净亏损占收入的比例为19%[29] - 加权平均普通股股数为5.9856亿股[29]

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Oddity Tech Ltd. (NASDAQ: ODD) between July 19, 2023 and May 20, 2024, both dates inclusive (the “Class Period”), of the important September 17, 2024 lead plaintiff deadline. SO WHAT: If you purchased Oddity Tech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) between October 31, 2022 and March 26, 2024, both dates inclusive (the “Class Period”), of the important September 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased SeaStar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024. SO WHAT: If you purchased stock or sold puts of M ...

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline. SO WHAT: If you purchased CVS Securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SeaStar Medical Holding Corporation (NASDAQ: ICU, ICUCW) between October 31, 2022 and March 26, 2024, both dates inclusive (the “Class Period”), of the important September 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased SeaStar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class B common stock of NIKE, Inc. (NYSE: NKE) between March 19, 2021 and March 21, 2024, both dates inclusive (the “Class Period”), of the important August 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased NIKE Class B common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...